Mesoblast (NASDAQ:MESO) Upgraded at Cantor Fitzgerald

Cantor Fitzgerald upgraded shares of Mesoblast (NASDAQ:MESO) to a strong-buy rating in a research report sent to investors on Tuesday,Zacks.com reports.

MESO has been the topic of several other research reports. Jefferies Financial Group lowered Mesoblast from a “buy” rating to a “hold” rating in a research report on Monday, December 23rd. Piper Sandler reissued an “overweight” rating and set a $24.00 target price (up previously from $15.00) on shares of Mesoblast in a research report on Friday, February 7th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $18.00.

Mesoblast Price Performance

Shares of Mesoblast stock opened at $14.71 on Tuesday. The business has a 50-day moving average of $18.03 and a 200 day moving average of $12.25. Mesoblast has a 12 month low of $1.99 and a 12 month high of $22.00. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.18 and a current ratio of 1.18.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Cubist Systematic Strategies LLC increased its position in Mesoblast by 241.0% during the fourth quarter. Cubist Systematic Strategies LLC now owns 35,191 shares of the company’s stock worth $697,000 after buying an additional 24,870 shares during the period. Bank of America Corp DE increased its position in Mesoblast by 1,503.3% during the fourth quarter. Bank of America Corp DE now owns 290,728 shares of the company’s stock worth $5,756,000 after buying an additional 272,595 shares during the period. BNP Paribas Financial Markets increased its position in Mesoblast by 86,566.7% during the fourth quarter. BNP Paribas Financial Markets now owns 2,600 shares of the company’s stock worth $51,000 after buying an additional 2,597 shares during the period. Tower Research Capital LLC TRC acquired a new position in Mesoblast during the fourth quarter worth approximately $88,000. Finally, Jump Financial LLC acquired a new position in Mesoblast during the fourth quarter worth approximately $205,000. Institutional investors and hedge funds own 1.43% of the company’s stock.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.